Tarsier

Tarsier Pharma Announces Successful Type C Meeting with FDA for TRS01 in Noninfectious Uveitis

Retrieved on: 
Monday, November 13, 2023
Safety, Food, Type, Uveitic glaucoma, IOP, Patient, FDA, Intraocular pressure, Master of Science, Inflammation, Pharmaceutical industry, Tarsier

TEL-AVIV, Israel, Nov. 13, 2023 /PRNewswire/ -- Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing first-in-class new therapies for the treatment of blinding ocular diseases, today announced the successful outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of TRS01 eye drop formulation for the treatment of noninfectious uveitis into a registrational program based on the recently completed TRS4Vision trial.

Key Points: 
  • "We are grateful for the FDA's support and guidance and look forward to continue the professional discussions as we advance TRS01 development."
  • The Type C meeting was supported by results from the previously completed TRS4Vision trial – a randomized, double-masked, active-controlled Phase 3 trial that was designed to evaluate the efficacy and safety of TRS01 eye drop formulation in noninfectious uveitis patients including uveitic glaucoma patients.
  • The upcoming trial is intended to replicate the TRS4Vision trial, with a revised endpoints in accordance with FDA discussions.
  • The data thus far support that the TRS01 profile has the potential to slow or prevent clinically meaningful progression of glaucoma in noninfectious uveitis and serve as first line treatment in uveitic glaucoma," said Professor Nguyen.

Tarsier Pharma Announces Publication of Review Article on Suppressing Inflammation for Treating Retinal Blinding Ocular Diseases, Highlighting dazdotuftide (TRS) as a Promising Therapeutic Candidate

Retrieved on: 
Monday, June 12, 2023
Biomedicine, Inflammation, Diabetes, Therapy, DME, AMD, Diabetic retinopathy, TRS, DR, Intravitreal injection, Retina, Potential New Boyfriend, Open access, DE, TEL, VEGF, Patient, Division, Treatment, Tarsier, NRP1, TLR, Pharmaceutical industry, Ophthalmology

The peer reviewed article "Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate", has been published as Open Access in the journal Biomedicines in May 2023.

Key Points: 
  • The peer reviewed article "Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate", has been published as Open Access in the journal Biomedicines in May 2023.
  • Dazdotuftide demonstrates the ability to target multiple inflammatory pathways, such as NRP1, TLR, and ACE-2, while simultaneously activating anti-inflammatory macrophages.
  • This groundbreaking approach positions dazdotuftide as a potential therapeutic option for effectively managing DR, DME, and AMD.
  • "Dazdotuftide represents an innovative therapeutic approach that addresses the unmet medical need for effective treatment of diseases such as AMD, DE, and DME," said Prof. Chowers. "

Tarsier Pharma announces International Non-proprietary Name for TRS

Retrieved on: 
Monday, April 24, 2023
Glaucoma, Intraocular pressure, IOP, International, TRS, World Health Organization, TEL, Ocular hypertension, Patient, Risk, Uveitic glaucoma, Uveitis, Tarsier, Steroid, WHO, Paratriathlon, Safety, Generic drug, Pharmaceutical industry

TEL AVIV, Israel, April 24, 2023 /PRNewswire/ -- Tarsier Pharma Ltd., a late-stage pharmaceutical company, announced today that its first-in-class immunomodulator TRS has been granted an International Nonproprietary Name (INN) of 'Dazdotuftide"' and has been placed on the INN Recommended List by the World Health Organization (WHO).

Key Points: 
  • TEL AVIV, Israel, April 24, 2023 /PRNewswire/ -- Tarsier Pharma Ltd., a late-stage pharmaceutical company, announced today that its first-in-class immunomodulator TRS has been granted an International Nonproprietary Name (INN) of 'Dazdotuftide"' and has been placed on the INN Recommended List by the World Health Organization (WHO).
  • "Achieving an INN- Dazdotuftide is another milestone in our journey to bring TRS to patients in need.
  • We are in exciting times, as we are wrapping up the first comprehensive, multi-center, global phase 3 clinical trial and expecting results by the third quarter of this year," said Daphne Haim-Langford, CEO of Tarsier Pharma.
  • Tarsier is developing TRS as an eye drop formulation (TRS01) and as slow-release biodegradable intravitreal injections (TRS02) targeting back-of-the-eye indications with an underlying inflammatory pathology, such as Diabetic Macular Edema, Non-Proliferative Diabetic Retinopathy, and others.

Tarsier Announces New Company Name: Walaris

Retrieved on: 
Thursday, September 29, 2022
Software, Other Defense, Drones, Technology, Defense, Artificial Intelligence, Security, Air, Transport, Aerospace, Other Technology, Manufacturing, Intelligence, Software, CEO, Technology, Solution, UAS, EO, Artificial intelligence, Government, Tarsier

Tarsier, the designer and developer of autonomous EO/IR-based drone detection, tracking, and identification systems for counter-UAS, perimeter surveillance, and critical infrastructure protection, announces Walaris as its new company name.

Key Points: 
  • Tarsier, the designer and developer of autonomous EO/IR-based drone detection, tracking, and identification systems for counter-UAS, perimeter surveillance, and critical infrastructure protection, announces Walaris as its new company name.
  • The Walaris name better reflects the companys core technical ethos and coincides with record revenue growth in 2022.
  • Walaris AirScout software is on the cutting edge of whats possible with artificial intelligence and computer vision today.
  • Formerly known as Tarsier, Walaris designs and develops autonomous optical-based drone detection, tracking, and identification systems for counter-UAS, perimeter surveillance, and critical infrastructure protection.

Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation

Retrieved on: 
Monday, August 15, 2022
Inflammation, CEO, Glaucoma, Standard of care, Clinical trial, Macular degeneration, Steroid, Multifocal choroiditis and panuveitis, Patient, TEL, Eye, Therapy, Severe cognitive impairment, COO, Safety, TRS, Uveitis, Retina, III, Investigational New Drug, Pharmaceutical industry, IND, Tarsier

It is currently being evaluated in a phase III clinical trial of TRS01 eye drops in patients with non-infectious anterior uveitis & uveitic glaucoma.

Key Points: 
  • It is currently being evaluated in a phase III clinical trial of TRS01 eye drops in patients with non-infectious anterior uveitis & uveitic glaucoma.
  • TRS02 is currently in pre-IND (Investigational New Drug) stage of development and is being further developed towards IND submission.
  • Dr. Daphne Haim-Langford, CEO & Chairperson of Tarsier Pharma, added: "Tarsier is an Ophthalmic company focusing on developing technologies to save sight for patients struggling with blinding diseases.
  • Together with our lead candidate, TRS01 eye drop formulation for front of the eye, TRS02 will enable the treatment of back-of-the-eye devastating diseases."

Tarsier™ Pharma is launching a dedicated website about uveitic glaucoma

Retrieved on: 
Wednesday, January 5, 2022
BD, Severe cognitive impairment, Community manager, Safety, Steroid, Therapy, Patient, Eye, Community, TEL, Pharma, Prognosis, TRS, Disease, Principal, Awareness, Inflammation, Optic nerve, Glaucoma, Population, Standard of care, Ophthalmology, Uveitis, Pharmaceutical industry, Tarsier

With this in mind, we are happy to take the lead in increasing awareness to the condition by launching this dedicated website for the benefit of the general public," said Tarsier Pharma's BD and Community Manager Ms. Ruti Friedel.

Key Points: 
  • With this in mind, we are happy to take the lead in increasing awareness to the condition by launching this dedicated website for the benefit of the general public," said Tarsier Pharma's BD and Community Manager Ms. Ruti Friedel.
  • Tarsier Pharma is phase-3 pharmaceutical company, focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular blinding diseases.
  • Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided due to their side effects of expediting glaucoma and vision loss.
  • Thus, TRS01 has the potential to become the standard of care for uveitic glaucoma.

Tarsier's CEO and Founder, Dr. Daphne Haim Langford, wins the 2021 EU Prize for Women Innovators

Retrieved on: 
Tuesday, November 30, 2021
Patient, CEO, Safety, Face, Commissioner, Small Business Innovation Research, Steroid, Woman, Culture, Autoimmunity, Inflammation, Israel Innovation Authority, Severe cognitive impairment, Nature, TRS, Investment, Education, Uveitis, Innovation, TEL, Glaucoma, Medicine, Tarsier, Standard of care, Glass, Daphne, Pharmaceutical industry

TEL AVIV, Israel, Nov. 30, 2021 /PRNewswire/ -- The EU Prize for Women Innovators is awarded to the most talented women entrepreneurs from across the EU and associated countries (including Israel), celebrating the women entrepreneurs behind game-changing innovations.

Key Points: 
  • TEL AVIV, Israel, Nov. 30, 2021 /PRNewswire/ -- The EU Prize for Women Innovators is awarded to the most talented women entrepreneurs from across the EU and associated countries (including Israel), celebrating the women entrepreneurs behind game-changing innovations.
  • MariyaGabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said:"It is a great privilege to award this prize to such exceptional innovators.
  • Daphne has over 20 years of experience in the biomedical industry as a serial investor, entrepreneur and executive.
  • Dr. Ami Appelbaum, Chairman of Israel Innovation Authority, said: "We would like to extend our heartfelt congratulations to Dr. Daphne Haim-Langford for winning the prestigious EU Prize for Women Innovators 2021.

First Patient Randomized in Tarsier Pharma's TRS4VISION Phase-III Clinical Trial in Patients with Active Non-Infectious Anterior Uveitis Including Patients with Uveitic Glaucoma

Retrieved on: 
Wednesday, September 22, 2021
Severe cognitive impairment, Steroid, Standard of care, Uveitis, Therapy, Inflammation, Patient, TEL, CEO, TRS, Tarsier, Founder, Safety, Glaucoma, Pharmaceutical industry

TRS4VISION is a Phase 3 randomized, active-controlled, double-masked study to evaluate the safety and efficacy of TRS01 eye drops in the treatment of subjects with active non-infectious anterior uveitis including subjects with uveitic glaucoma.

Key Points: 
  • TRS4VISION is a Phase 3 randomized, active-controlled, double-masked study to evaluate the safety and efficacy of TRS01 eye drops in the treatment of subjects with active non-infectious anterior uveitis including subjects with uveitic glaucoma.
  • TRS4VISION is planned to evaluate 162 patients in multiple uveitis referral centers in the US and Europe.
  • Tarsier's TRS01 is a potent fast-acting immunomodulator, delivered as eye drops, for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma that is considered an end-stage condition of uveitis.
  • Once a uveitis patient has also developed glaucoma (uveitic glaucoma), the only available treatments for active inflammation, which are steroids, should be avoided due to their side effects of expediting glaucoma and vision loss.